08.02.22
United Kingdom
www.gsk.com
Sales: $3.7 billion
Key Personnel: Emma Walmsley, CEO; Iain Mackay, CFO; Dr. Hal Barron, chief scientific officer and president, R&D; Diana Conrad, chief people officer; Brian McNamara, CEO, GSK Consumer Healthcare
Major Products: Oral care—Sensodyne, Polident/Corega, Parodontax, Biotene, Dr. Best and Aquafresh
New Products: Sensodyne Repair and Protect Deep Repair, Parodontax Active Gum Repair
Comments: Two months ago, GSK announced plans to demerge its consumer healthcare business to form Haleon, an independent company. GSK called the move the “most significant corporate change for GSK in the last 20 years, creating two new leading companies, each with clear targets for growth and the ability to positively impact the health and lives of billions of people.”
The move was expected to take place last month.
In 2021, corporate sales were flat, while consumer healthcare sales fell 4%.
According to GSK, a third of tooth sensitivity sufferers seek a long-lasting solution to address the cause of the pain, rather than just treat the symptoms. GSK’s answer? Sensodyne Repair and Protect Deep Repair, which is available in more than 25 markets. The formula provides deep and targeted repair within the dentine tubules, holes in the tissue beneath the tooth enamel that are the source of the pain, while also providing long-lasting protection from sensitivity.
Elsewhere, GSK introduced Parodontax Active Gum Repair. It is said to be clinically proven to help reverse the early signs of gum disease. GSK says a third of people globally suffer from bleeding gums, which may be a sign of gum disease.
For Q1 2022, corporate sales soared 32%. Consumer healthcare sales jumped 14%.
www.gsk.com
Sales: $3.7 billion
Key Personnel: Emma Walmsley, CEO; Iain Mackay, CFO; Dr. Hal Barron, chief scientific officer and president, R&D; Diana Conrad, chief people officer; Brian McNamara, CEO, GSK Consumer Healthcare
Major Products: Oral care—Sensodyne, Polident/Corega, Parodontax, Biotene, Dr. Best and Aquafresh
New Products: Sensodyne Repair and Protect Deep Repair, Parodontax Active Gum Repair
Comments: Two months ago, GSK announced plans to demerge its consumer healthcare business to form Haleon, an independent company. GSK called the move the “most significant corporate change for GSK in the last 20 years, creating two new leading companies, each with clear targets for growth and the ability to positively impact the health and lives of billions of people.”
The move was expected to take place last month.
In 2021, corporate sales were flat, while consumer healthcare sales fell 4%.
According to GSK, a third of tooth sensitivity sufferers seek a long-lasting solution to address the cause of the pain, rather than just treat the symptoms. GSK’s answer? Sensodyne Repair and Protect Deep Repair, which is available in more than 25 markets. The formula provides deep and targeted repair within the dentine tubules, holes in the tissue beneath the tooth enamel that are the source of the pain, while also providing long-lasting protection from sensitivity.
Elsewhere, GSK introduced Parodontax Active Gum Repair. It is said to be clinically proven to help reverse the early signs of gum disease. GSK says a third of people globally suffer from bleeding gums, which may be a sign of gum disease.
For Q1 2022, corporate sales soared 32%. Consumer healthcare sales jumped 14%.